M A Hassan Talukder Selected Research

4-Aminopyridine (4 Aminopyridine)

4/2022	Effects of 4-Aminopyridine on Combined Nerve and Muscle Injury and Bone Loss.
1/2021	(4-Aminopyridine)-PLGA-PEG as a Novel Thermosensitive and Locally Injectable Treatment for Acute Peripheral Nerve Injury.
1/2021	4-Aminopyridine: A Single-Dose Diagnostic Agent to Differentiate Axonal Continuity in Nerve Injuries.
11/2020	Human equivalent dose of oral 4-aminopyridine differentiates nerve crush injury from transection injury and improves post-injury function in mice.
1/2020	Transdermal delivery of 4-aminopyridine accelerates motor functional recovery and improves nerve morphology following sciatic nerve crush injury in mice.
1/2019	4-Aminopyridine attenuates muscle atrophy after sciatic nerve crush injury in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M A Hassan Talukder Research Topics

Disease

6	Crush Injuries 04/2022 - 01/2019
5	Peripheral Nerve Injuries 01/2021 - 01/2020
4	Muscular Atrophy (Muscle Atrophy) 04/2022 - 01/2019
3	Multiple Sclerosis 01/2021 - 01/2020
3	Myocardial Infarction 09/2015 - 10/2007
3	Ischemia 09/2015 - 12/2010
2	Wounds and Injuries (Trauma) 01/2021 - 03/2020
2	Inflammation (Inflammations) 01/2020 - 05/2006
2	Myocardial Ischemia (Ischemic Heart Diseases) 02/2011 - 03/2008
1	Dysbiosis 02/2022
1	Infections 02/2022
1	Paralysis (Palsy) 01/2021
1	Ileus 01/2021
1	Demyelinating Diseases (Demyelinating Disease) 11/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Insulin Resistance 03/2016
1	Cardiomyopathies (Cardiomyopathy) 03/2016
1	Heart Failure 01/2013
1	Infarction (Infarctions) 01/2013
1	Pulmonary Arterial Hypertension 03/2011
1	Heart Diseases (Heart Disease) 12/2009
1	Reperfusion Injury 05/2006

Drug/Important Bio-Agent (IBA)

6	4-Aminopyridine (4 Aminopyridine)FDA Link 04/2022 - 01/2019
3	Erythropoietin FDA Link 01/2021 - 03/2020
2	Pharmaceutical PreparationsIBA 01/2021 - 11/2020
1	Saline SolutionIBA 04/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 02/2022
1	Butyrates (Butyrate)IBA 02/2022
1	16S Ribosomal RNAIBA 02/2022
1	Erythropoietin Receptors (Erythropoietin Receptor)IBA 01/2021
1	Neuroprotective AgentsIBA 03/2020
1	Hormones (Hormone)IBA 03/2020
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020
1	Potassium Channel Blockers (Blockers, Potassium Channel)IBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 03/2016
1	Caveolin 3IBA 03/2016
1	PalmitatesIBA 03/2016
1	EnzymesIBA 09/2015
1	Proteins (Proteins, Gene)FDA Link 09/2015
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2013
1	NG-Nitroarginine Methyl Ester (L-NAME)IBA 01/2013
1	dimethylarginineIBA 03/2011
1	Thyroid HormonesIBA 02/2011
1	CalciumIBA 12/2009
1	Adenosine Triphosphatases (ATPase)IBA 03/2008
1	Protein Isoforms (Isoforms)IBA 10/2007
1	Free RadicalsIBA 05/2006
1	Oxidants (Oxidizing Agents)IBA 05/2006

Therapy/Procedure

2	Injections 01/2021 - 11/2020
1	Therapeutics 02/2022
1	Surgical Amputation (Amputations) 01/2021
1	Electrodes (Electrode) 01/2021
1	Cutaneous Administration 01/2020
1	Laser Therapy (Surgery, Laser) 01/2020
1	Ischemic Postconditioning 12/2010